Liver and Bone Metastases From Small Bowel Neuroendocrine Tumor Respond to 177Lu-DOTATATE Induction and Maintenance Therapies

被引：3
作者：
Makis, William [1 ]
McCann, Karey [1 ]
Buteau, Francois A. [1 ]
McEwan, Alexander J. B. [1 ]
机构：
[1] Cross Canc Inst, Dept Diagnost Imaging, Edmonton, AB T6G 1Z2, Canada
来源：
CLINICAL NUCLEAR MEDICINE | 2015年 / 40卷 / 02期
关键词：
lutetium; Lu-177-DOTATATE; PRRT; bone metastases; carcinoid; neuroendocrine tumor; RECEPTOR RADIONUCLIDE THERAPY;
D O I：
10.1097/RLU.0000000000000569
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
A 73-year-old man diagnosed with small bowel neuroendocrine tumor (NET) with liver and bone metastases was treated with 4 induction cycles and 2 maintenance cycles of Lu-177-DOTATATE peptide receptor radionuclide therapy (PRRT). His symptoms and mobility improved significantly following induction as well as maintenance treatments, and posttherapy imaging studies showed significant improvement in metastatic liver and bone disease. Current protocols consisting of 4 induction cycles of Lu-177-DOTATATE only may not be sufficient to optimally treat neuroendocrine liver and bone metastases, and further research into maintenance Lu-177-DOTATATE therapy is warranted.
引用
收藏
页码：162 / 165
页数：4
相关论文
共 14 条
[1]   Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence [J].
Campana, Davide ;
Capurso, Gabriele ;
Partelli, Stefano ;
Nori, Francesca ;
Panzuto, Francesco ;
Tamburrino, Domenico ;
Cacciari, Giulia ;
Delle Fave, Gianfranco ;
Falconi, Massimo ;
Tomassetti, Paola .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (08) :1197-1205
[2]   Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours [J].
Claringbold, Phillip G. ;
Brayshaw, Paul A. ;
Price, Richard A. ;
Turner, J. Harvey .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (02) :302-311
[3]   Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy [J].
Ezziddin, Samer ;
Opitz, Martin ;
Attassi, Mared ;
Biermann, Kim ;
Sabet, Amir ;
Guhlke, Stefan ;
Brockmann, Holger ;
Willinek, Winfried ;
Wardelmann, Eva ;
Biersack, Hans-Juergen ;
Ahmadzadehfar, Hojjat .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (03) :459-466
[4]   Carcinoid metastasis to the brain [J].
Hlatky, R ;
Suki, D ;
Sawaya, R .
CANCER, 2004, 101 (11) :2605-2613
[5]   Lutetium-labelled peptides for therapy of neuroendocrine tumours [J].
Kam, B. L. R. ;
Teunissen, J. J. M. ;
Krenning, E. P. ;
de Herder, W. W. ;
Khan, S. ;
van Vliet, E. I. ;
Kwekkeboom, D. J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 :103-112
[6]  
Kos-Kudla Beata, 2008, Endokrynol Pol, V59, P41
[7]   Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors [J].
Kwekkeboom, Dik J. ;
de Herder, Wouter W. ;
van Eijck, Casper H. J. ;
Kam, Boen L. ;
van Essen, Martijn ;
Teunissen, Jaap J. M. ;
Krenning, Eric P. .
SEMINARS IN NUCLEAR MEDICINE, 2010, 40 (02) :78-88
[8]   Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors [J].
Kwekkeboom, DJ ;
Teunissen, JJ ;
Bakker, WH ;
Kooij, PP ;
de Herder, WW ;
Feelders, RA ;
van Eijck, CH ;
Esser, JP ;
Kam, BL ;
Krenning, EP .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2754-2762
[9]   Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France [J].
Lombard-Bohas, C. ;
Mitry, E. ;
O'Toole, D. ;
Louvet, C. ;
Pillon, D. ;
Cadiot, G. ;
Borson-Chazot, F. ;
Aparicio, T. ;
Ducreux, M. ;
Lecomte, T. ;
Etienne, P. L. ;
Cacheux, W. ;
Legoux, J. L. ;
Seitz, J. F. ;
Ruszniewski, P. ;
Chayvialle, J. A. ;
Rougier, P. .
NEUROENDOCRINOLOGY, 2009, 89 (02) :217-222
[10]  
Meijer WG, 2003, J NUCL MED, V44, P184
12